Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Innovent Biologics Inc
(OP:
IVBXF
)
5.380
+0.470 (+9.57%)
Streaming Delayed Price
Updated: 2:12 PM EDT, May 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
19,600
Open
5.380
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
4.910
Today's Range
5.380 - 5.380
52wk Range
3.550 - 6.410
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
April 06, 2024
ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates...
Via
Talk Markets
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
March 23, 2024
Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility.
Via
Talk Markets
Performance
YTD
-0.37%
-0.37%
1 Month
+11.73%
+11.73%
3 Month
+33.00%
+33.00%
6 Month
-8.50%
-8.50%
1 Year
+3.66%
+3.66%
More News
Read More
Week In Review: EurekaBio Raises $40 Million To Support Lentiviral Vector Platform
March 09, 2024
Via
Talk Markets
Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal
March 02, 2024
Via
Talk Markets
Sanofi, Innovent Biologics Collaborate On Cancer Treatments In China
August 04, 2022
Via
Benzinga
Week In Review: AlphaGen And ArtBio Form China-US Radioligand Partnership
February 24, 2024
Via
Talk Markets
Week In Review: I-Mab Morphs Into US-Only Company; Sells China Assets For $80 Million
February 11, 2024
Via
Talk Markets
Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal
December 31, 2023
Via
Talk Markets
Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments
December 02, 2023
Via
Talk Markets
Week In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7 Billion
November 04, 2023
Via
Talk Markets
Week In Review: A Consortium Of China Drug Distributors Want To Acquire Poland's Neuca
August 26, 2023
Via
Talk Markets
Week In Review: Billion Dollar Deals - Moderna’s Shanghai Investment And F-Star’s Takeda Collaboration
July 08, 2023
Via
Talk Markets
Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million Upfront
July 01, 2023
Via
Talk Markets
Week In Review: Cullgen Signs $1.9 Billion Protein Degrader Deal With Astellas
June 17, 2023
Via
Talk Markets
Week In Review: Shanghai HighTide Therapeutics Files For Hong Kong IPO
June 10, 2023
Via
Talk Markets
Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC
May 13, 2023
Via
Talk Markets
Week In Review: China Biopharmas Announce Three Out-Licensing Deals Totaling $2 Billion
February 18, 2023
Via
Talk Markets
Week In Review: Structure Stages $161 Million US IPO For AI/Structure-Based Drug Development
February 04, 2023
Via
Talk Markets
Week In Review: Boston Scientific Pays $523 Million For Majority Stake In Beijing Acotec Scientific
December 17, 2022
Via
Talk Markets
Week In Review: Akeso Out-Licenses PD-1/VEGF To Summit In $5 Billion Pact
December 10, 2022
Via
Talk Markets
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
April 14, 2022
Via
Benzinga
The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy
April 06, 2022
Via
Benzinga
FDA Rejects Lilly's Sintilimab/Chemo Combo Therapy In First-Line Lung Cancer Setting
March 24, 2022
Via
Benzinga
FDA AdComm Votes Against Lilly's Lung Cancer Drug, Sintilimab
February 11, 2022
Via
Benzinga
Innovent Biologics, UNION therapeutics Ink Licensing Pact For Inflammatory Dermatology Candidate
September 28, 2021
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.